Reported 0 shares, down 150,000 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-06-30 | 32982007 |
| 2023-09-30 | 42077214 |
| 2023-12-31 | 59091079 |
| 2024-03-31 | 58516057 |
| 2024-06-30 | 24943406 |
| 2024-09-30 | 19018015 |
| 2024-12-31 | 0 |
| 2025-03-31 | 7446000 |
| 2025-06-30 | 0 |
| 2025-12-31 | 35793502 |
| 2026-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2026 | Reduced | 0 | -450,743 (-100.0%) | 0 | $0 | 2026-05-15 | |
| Q4 2025 | New | 450,743 | +450,743 (0.0%) | 0.64% | $35,793,502 | 2026-02-17 | |
| Q2 2025 | Reduced | 0 | -150,000 (-100.0%) | 0 | $0 | 2025-08-14 | |
| Q1 2025 | New | 150,000 | +150,000 (0.0%) | 0.26% | $7,446,000 | 2025-05-15 | |
| Q4 2024 | Reduced | 0 | -387,017 (-100.0%) | 0 | $0 | 2025-02-14 | |
| Q3 2024 | Reduced | 387,017 | -166,420 (-30.1%) | 0.4% | $19,018,015 | 2024-11-14 | |
| Q2 2024 | Reduced | 553,437 | -386,429 (-41.1%) | 0.6% | $24,943,406 | 2024-08-14 | |
| Q1 2024 | Reduced | 939,866 | -83,179 (-8.1%) | 1.02% | $58,516,057 | 2024-05-15 | |
| Q4 2023 | Added | 1,023,045 | +127,404 (14.2%) | 1.32% | $59,091,079 | 2024-02-14 | |
| Q3 2023 | Added | 895,641 | +152,803 (20.6%) | 1.4% | $42,077,214 | 2023-11-14 | |
| Q2 2023 | New | 742,838 | +742,838 (0.0%) | 0.95% | $32,982,007 | 2023-08-14 |
Who else reported the position
183 managers reported DISC MEDICINE INC COM(DE) for Q2 2025.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 3,245,710 | +21,329 | < 0.01% | $171,892,802 | 11 qtrs |
| Atlas Venture Life Science Advisors LLC | Unchanged | 2,384,456 | 0 | 19.07% | $126,280,790 | 11 qtrs |
| BlackRock Inc | Reduced | 2,044,827 | -49,733 | < 0.01% | $108,294,039 | 4 qtrs |
| Frazier Life Sciences Management L P | Reduced | 1,654,834 | -100,000 | 3.5% | $87,640,009 | 9 qtrs |
| RA CAPITAL MANAGEMENT L P | Unchanged | 1,577,106 | 0 | 1.41% | $83,523,534 | 2 qtrs |
| JANUS HENDERSON GROUP PLC | Added | 1,553,961 | +130,702 | 0.04% | $82,250,008 | 11 qtrs |
| PRICE T ROWE ASSOCIATES INC MD | Added | 1,515,625 | +157,371 | < 0.01% | $80,268,000 | 9 qtrs |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 1,432,090 | -911,409 | 0.01% | $75,843,487 | 9 qtrs |
| ORBIMED ADVISORS LLC | Unchanged | 1,415,020 | 0 | 1.88% | $74,939,459 | 11 qtrs |
| VANGUARD GROUP INC | Added | 1,396,736 | +91,690 | < 0.01% | $73,971,138 | 11 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2025
- Filed
- August 14, 2025
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.